BioInsights - Supporting development of mRNA-based therapies by addressing large-scale purification challenges

Supporting development of mRNA-based therapies by addressing large-scale purification challenges

Cell & Gene Therapy Insights 2021; 7(5), 489–502

10.18609/cgti.2021.073

Published: 6 June 2021
Innovator Insight
Kelly Flook

The field of mRNA-based therapies is a rapidly emerging area with increasing real-world applications. The potential of these therapies is being demonstrated in various fields. Although the potential of mRNA in therapies is seemingly endless, obtaining the quantities of synthetic mRNA needed for clinical treatment remains a challenging obstacle, and current methods for mRNA purification are creating a bottleneck in large-scale manufacturing. Particularly for vaccine development, obtaining the quantities of synthetic mRNA needed for clinical treatment remains an obstacle. As a result, a robust, scalable and easy-to-use platform to support all mRNA therapies is needed. To support the development of mRNA-based therapies, Thermo Fisher Scientific has developed an affinity resin for the purification and isolation of mRNA from in vitro transcription (IVT) manufacturing processes. The following article and case studies will highlight how the Thermo Scientific POROS™ Oligo (dT)25 affinity resin can enable efficient and simplified mRNA purification.